Flexion Therapeutics Inc. (NASDAQ:FLXN) finished Wednesday with an addition of $0.08 to close at $9.38, an upside of 0.86 percent. An average of 8,713,540 shares of common stock have been traded in the last five days. There was a gain of $3.33 in the past week. The last 20 days have seen an average of 3,014,570 shares traded, while the 50-day average volume stands at 2,036,734.
FLXN stock has increased by 58.18% in the last month. The company shares reached their 1-month lowest point of $5.40 on 10/08/21. With the stock rallying to its 52-week high on 01/15/21, shares of the company touched a low of $4.30 and a high of $13.66 in 52 weeks. In spite of this, the price is down -31.33% from the 52-week high.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
87 days have passed since Flexion Therapeutics Inc. (FLXN) last reported insider trading activity. Willwerth Christina, who is Chief Strategy Officer, most recently acquired $3,945 shares at $6.45 per share on Jul 19. In this transaction, the insider spent $25,445. Chief Regulatory Officer, Wentworth Kerry, disposed of 3,944 shares at a price of $6.45 on Jul 19. The insider now owns more than $25,439 worth of shares. Prior to that, Chief Business Officer Muzikant Adam went on to Sale 1,870 shares at $6.45 each on Jul 19. An amount of $12,062 was transacted.
Flexion Therapeutics Inc. (FLXN) has a trailing price-to-earnings (P/E) ratio of 23.00 for the broader industry and 32.30 for the sector. The stock’s beta is 1.31. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 4.49.
The quick ratio of Flexion Therapeutics Inc. for the three months ended June 29 was 4.30, and the current ratio was 4.60, indicating that the company is able to meet its debt obligations. Flexion Therapeutics Inc.’s EBITDA margin for the year ending June 29 is -104.82%, while its operating margin for the same period stands at -71.20%. Its gross profit as reported stood at $66.3 million compared to revenue of $85.55 million.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Flexion Therapeutics Inc.’s return on assets was -39.80%, compared to -46.9% over the last five years.
For the three-month period that ended June 29, Flexion Therapeutics Inc. had $23.62 million in cash. The analyst consensus anticipated Flexion Therapeutics Inc.’s latest quarter earnings to come in at -$0.5 per share, but it turned out to be -$0.44, a 12.00% surprise. For the quarter, EBITDA amounted to -$13.23 million. Shareholders own equity worth $50.29 million.
From a technical analysis perspective, let’s take a brief look at Flexion Therapeutics Inc. (FLXN) price momentum. RSI 9-day as of the close on 13 October was 81.75%, suggesting the stock is Overbought, with historical volatility in this time frame at 232.69%.
As of today, FLXN’s price is $7.86 +55.04% or $3.33 from its 5-day moving average. FLXN is currently trading +48.42% higher than its 20-day SMA and +10.87% higher than its 100-day SMA. However, the stock’s current price level is +55.30% above the SMA50 and -23.49% below the SMA200.
The stochastic %K and %D were 86.49% and 63.72%, respectively, and the average true range (ATR) was 0.68. With the 14-day stochastic at 88.64% and the average true range at 0.60, the RSI (14) stands at 75.75%. The stock has reached 2.20 on the 9-day MACD Oscillator while the 14-day reading was at 2.47.
The consensus rating for Flexion Therapeutics Inc. (FLXN) among analysts is Overweight. According to current brokerage recommendations, 0 brokerage firms advise that investors sell FLXN, while 4 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 4 others rate it as a “buy”.
What is FLXN’s price target for the next 12 months?
Analysts predict a range of price targets between $10.00 and $25.00, with a median target of $12.00. Taking a look at these predictions, the average price target given by analysts for Flexion Therapeutics Inc. (FLXN) stock is $13.86.